This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
HCA Beats Q2 Earnings on Higher Admissions, Ups '25 EPS View
by Zacks Equity Research
HCA Healthcare's Q2 earnings rose 24% year over year on stronger patient volumes. EPS for 2025 is expected to be within $25.5-$27, up from the earlier view of $24.05-$25.85.
Hologic's International Momentum Takes Shape: Will Execution Pay Off?
by Moumi Mondal
HOLX is leaning into international growth with Surgical division strength and untapped demand driving momentum abroad.
The Zacks Analyst Blog Highlights Wells Fargo, Abbott Laboratories, American Express, TSS and Maui Land & Pineapple
by Zacks Equity Research
Wells Fargo, Abbott, and American Express lead Zacks highlights, while TSS surges on AI growth and MLP eyes land monetization.
Top Stock Reports for Wells Fargo, Abbott & American Express
by Mark Vickery
Wells Fargo gains post-Fed cap removal, Abbott rides strong devices pipeline, while AmEx sees growth but rising costs pinch margins.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View
by Zacks Equity Research
THC's Q2 earnings benefit on the back of strong volumes, facility buyouts, higher acuity and favorable payer mix. It currently expects 2025 adjusted EPS within $15.55-$16.21, up from the earlier view of $11.99-$13.12.
NVST or ABT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NVST vs. ABT: Which Stock Is the Better Value Option?
Is Hologic Stock a Risky Investment Ahead of Its Q3 Earnings Report?
by Moumi Mondal
HOLX heads into Q3 earnings with revenue and EPS estimates down, tariff pressures mounting, and stock lagging peers.
Stock Market News for Jul 18, 2025
by Zacks Equity Research
U.S. stocks ended higher on Thursday, with the S&P 500 and the Nasdaq closing at new record highs, as fresh economic data and solid earnings from a slew of big companies bolstered investors' faith in the economy.
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year?
by Zacks Equity Research
Here is how Abbott (ABT) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.
Down 9.0% in 4 Weeks, Here's Why Abbott (ABT) Looks Ripe for a Turnaround
by Zacks Equity Research
Abbott (ABT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Abbott Stock Falls in Pre-Market Despite Q2 Earnings and Sales Beat
by Zacks Equity Research
ABT beats on Q2 earnings and revenues with double-digit growth in Medical Devices, yet shares fall 5% pre-market.
Abbott (ABT) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Abbott (ABT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of +0.80% and +0.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Markets Fight Off Powell Rumor, Close in the Green
by Mark Vickery
A report that President Trump intended on firing Fed Chair Jerome Powell sent all major indexes into the loss column temporarily.
Top Analyst Reports for Exxon Mobil, Home Depot & IBM
by Mark Vickery
XOM, HD, and IBM face distinct macro pressures, but AI, Permian strength, and digital upgrades continue to fuel long-term growth.
Is it Prudent to Retain Charles River Stock in Your Portfolio Now?
by Zacks Equity Research
CRL sees momentum in drug discovery and safety services, but macro pressures and currency headwinds threaten growth.
3 Medical Stocks to Watch as Q2 Earnings Approach: ABT, JNJ, NVS
by Shaun Pruitt
The broader market's historic rebound may make it necessary to consider some defensive positions in the portfolio, and these medical stocks fit the bill ahead of their Q2 reports.
Will Robust MedSurg Performance Fuel Boston Scientific's Q2 Earnings?
by Zacks Equity Research
BSX eyes strong Q2 with MedSurg momentum, solid Cardiovascular growth and benefits from key tech acquisitions.
Countdown to Abbott (ABT) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Abbott (ABT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
ABT to Report Q2 Earnings: CGM and Cardiac Devices in Focus
by Zacks Equity Research
Abbott eyes Q2 growth with strong CGM momentum, cardiac device wins and resilient performance across key segments.
Abbott (ABT) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Abbott (ABT) reached $132.02 at the closing of the latest trading day, reflecting a -1.18% change compared to its last close.
Smart Money Going in Senior Health: Key Stocks in Elderly Care
by Urmimala Biswas
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.
Abbott (ABT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ABT's FreeStyle Libre 3 Plus Now Available in Canada: Stock to Rise?
by Zacks Equity Research
Abbott debuts FreeStyle Libre 3 Plus in Canada, enhancing diabetes care with the world's smallest glucose sensor.